New ways to treat Duchenne muscular dystrophy

Beyond Biotech - the podcast from Labiotech

Player FM - Internet Radio Done Right

تمت الإضافة منذ قبل three أعوام

المحتوى المقدم من Labiotech. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Labiotech أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.

The Vanished

1
Lost on Route 66: The Disappearance of Diana Hayes 6:47

منذ 5 weeks6:47

التشغيل لاحقا

قوائم

إعجاب

احب

6:47

Was she the victim of foul play, an accident, or did she choose to disappear? In this episode of The Vanished, we retrace Diana’s last known movements, strange witness accounts, and the lingering mystery that has never been solved or.. was never meant to be solved.

منذ عام واحد 23:56

MP3•منزل الحلقة

Duchenne muscular dystrophy (DMD) is a genetic disorder with progressive muscle degeneration and weakness due to changes in the protein dystrophin, which helps keep muscle cells intact.

There are few treatments for DMD, although recent advances mean that males – who are primarily affected by DMD – can now sometimes survive into their 30s.
More drugs are being developed in the fight against DMD, and this week we had a conversation with Frank Gleeson, CEO of Satellos Bioscience, about recent work on addressing DMD, including the company’s own work in the field.

00:47-02:01: About Satellos Bioscience
02:01-04:33: What is Duchenne muscular dystrophy?
04:33-05:43: What are the challenges in treating Duchenne muscular dystrophy?
05:43-09:08: What are the new treatments for Duchenne muscular dystrophy?
09:08-11:20: What is your treatment for Duchenne muscular dystrophy?
11:20-13:42: Are there different approaches to treating Duchenne muscular dystrophy?
13:42-14:06: How is your treatment delivered?
14:06-17:32: How important is early intervention?
17:32-18:56: Where is Satellos at with clinical trials?
18:56-20:41: Preclinical trial results
20:41-21:44: Outreach to the Duchenne muscular dystrophy community
21:44-23:12: Is a cure for Duchenne muscular dystrophy possible?

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

فصول

1. New ways to treat Duchenne muscular dystrophy (00:00:00)

2. About Satellos Bioscience (00:00:47)

3. What is Duchenne muscular dystrophy?  (00:02:01)

4. What are the challenges in treating Duchenne muscular dystrophy?  (00:04:33)

5. What are the new treatments for Duchenne muscular dystrophy? (00:05:43)

6. What is your treatment for Duchenne muscular dystrophy?  (00:09:08)

7. Are there different approaches to treating Duchenne muscular dystrophy?  (00:11:20)

8. How is your treatment delivered? (00:13:42)

9. How important is early intervention? (00:14:06)

10. Where is Satellos at with clinical trials?  (00:17:32)

11. Preclinical trial results  (00:18:56)

12. Outreach to the Duchenne muscular dystrophy community  (00:20:41)

13. Is a cure for Duchenne muscular dystrophy possible? (00:21:44)

137 حلقات

#News #Tech News #Labiotech

New ways to treat Duchenne muscular dystrophy

Beyond Biotech - the podcast from Labiotech

published منذ عام واحد

MP3•منزل الحلقة

Duchenne muscular dystrophy (DMD) is a genetic disorder with progressive muscle degeneration and weakness due to changes in the protein dystrophin, which helps keep muscle cells intact.

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

فصول

1. New ways to treat Duchenne muscular dystrophy (00:00:00)

2. About Satellos Bioscience (00:00:47)

3. What is Duchenne muscular dystrophy?  (00:02:01)

4. What are the challenges in treating Duchenne muscular dystrophy?  (00:04:33)

5. What are the new treatments for Duchenne muscular dystrophy? (00:05:43)

6. What is your treatment for Duchenne muscular dystrophy?  (00:09:08)

7. Are there different approaches to treating Duchenne muscular dystrophy?  (00:11:20)

8. How is your treatment delivered? (00:13:42)

9. How important is early intervention? (00:14:06)

10. Where is Satellos at with clinical trials?  (00:17:32)

11. Preclinical trial results  (00:18:56)

12. Outreach to the Duchenne muscular dystrophy community  (00:20:41)

13. Is a cure for Duchenne muscular dystrophy possible? (00:21:44)

137 حلقات

#News #Tech News #Labiotech

كل الحلقات

1
The TCR-T cell therapies of tomorrow 26:42

منذ 5 أيام26:42

26:42

Sweden's fastest growing private biotech, Anocca, is making plans for clinical trials in pancreatic cancer, with the TCR-T cell therapy trials called VIDAR-1. The CEO, Reagan Jarvis, when a researcher, pitched the company idea to a leading Swedish industrialist, who became co-founder, and provided the initial financing. The company has raised more than €100m to date. On the podcast this week, we have a conversation with Jarvis about TCR-T cell therapies, creating off-the-shelf products and partnerships with EmendoBio and Shinobi Therapeutics. 00:43-02:10: About Anocca 02:10-04:16: About TCR-T cell therapies and their use in treatments 04:16-06:02: Anocca’s approach to T-cell biology, cutting-edge biotechnologies and integrated software 06:02-07:58: A different approach to other cell and gene therapy companies 07:58-09:16: Facing challenges 09:16-10:48: Addressing conditions and diseases 10:48-11:54: Pancreatic cancer 11:54-13:40: What represents success for Anocca? 13:40-14:09: What is VIDAR-1? 14:09-16:08: Partnerships 16:08-18:05: Scaling up and addressing costs 18:05-20:07: How is TCR-T therapy evolving? 20:07-23:11: The impact of artificial intelligence 23:11-25:16: Anocca timeline 25:16-25:57: Closing comments ` Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

1
Can RNA drugs solve the obesity epidemic? 29:56

منذ 12 يومًا29:56

29:56

Resalis Therapeutics is pursuing a groundbreaking approach to obesity treatment. Unlike current therapies that primarily focus on appetite suppression, Resalis’ lead program, RES-010, is a non-coding RNA drug candidate that targets underlying biological pathways to promote sustainable weight loss. By enhancing energy expenditure through white-to-brown adipose tissue conversion while preserving muscle mass, RES-010 is positioned as an ideal standalone therapy or a synergistic option for long-term weight management. The company recently initiated a phase 1 study in December 2024 for RES-010 in healthy and obese subjects, and they also secured an equity investment from Sanofi in October 2024. To talk about ways to tackle obesity, and Resalis’ approach, our guest on the podcast this week is Alessandro Toniolo, CEO of Resalis Therapeutics. 00:57-05:06: About Resalis Therapeutics 05:06-08:59: Issues of obesity 08:59-13:20: Companies working on obesity treatments 13:20-15:34: Does suppressing appetite affect nutrition? 15:34-17:49: Introduction of new obesity treatments 17:49-21:33: Approaches other than appetite suppression 21:33-22:38: RES-010 mode of action 22:38-24:04: Administration methods 24:04-25:11: Clinical trials 25:11-26:38: Resalis’ pipeline 26:38-28:08: Next steps for Resalis 28:08-28:36: Effect of obesity on other parts of the body 28:36-29:06: Final comments ` Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

1
Reversing cancer mechanisms to fight back against solid tumors 21:24

منذ 19 يومًا21:24

21:24

CatalYm is preparing to initiate its broad phase 2b clinical development program for visugromab to tackle multiple solid tumor indications. Visugromab is a monoclonal antibody that neutralizes the tumor-derived growth differentiation factor-15 (GDF-15), a locally acting immunosuppressant fostering immunotherapy resistance. Neutralizing GDF-15 with visugromab reverses key cancer resistance mechanisms to reinstate an efficient anti-tumor response by reenabling immune cell activation, proliferation and Interferon-γ signature induction. Visugromab has demonstrated a good safety profile and potent and durable anti-tumor efficacy in combination with anti-PD-1 treatment in advanced cancer patients, as highlighted in its recent Nature publication and interim clinical data. This week we have a conversation with Eugen Leo, chief medical officer at CatalYm. 01:30-03:38: About CatalYm 03:38-06:59: Solid tumors and also why they are hard to treat 06:59-09:04: Current treatments for solid tumors 09:04-10:47: What is immunotherapy resistance? 10:47-12:23: What is visugromab? 12:23-13:32: CatalYm’s clinical development program 13:32-15:12: What represents success for patients using visugromab? 15:12-17:50: Other treatment options being developed 17:50-19:50: CatalYm’s pipeline and the future This week’s podcast was sponsored by TCR Solutions . Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

1
Targeting the dark genome to develop new therapies to fight obesity 32:32

منذ 26 يومًا32:32

32:32

In the fall of 2024, Haya Therapeutics, based in Switzerland and San Diego, landed a $1bn deal with Eli Lilly to apply its long non-coding RNA (ncRNA) technology to obesity. The company’s lead candidate, HTX-001, is making progress towards the clinic in cardiomyopathy. CEO Samir is one of the first researchers to publish on lncRNA – which is also known as the Dark Genome This week, our podcast guest is Samir Ounzain, CEO and co-founder of Haya Therapeutics. Ounzain was one of the first researchers to publish on lncRNA, also known as the ‘dark genome.’ 00:55-03:47: About Haya Therapeutics 03:47-06:37: What is the dark genome? 06:37-09:29: What is the connection between lncRNA and disease? 09:30-13:22: How can disease be addressed via the dark genome? 13:22-16:45: Which diseases are you tackling? 16:45-18:02: What is the EchoHAYA platform? 18:02-21:07: How does your lead candidate, HTX-001, work? 21:07-22:00: Is the objective stopping fibrosis or reversing it? 22:00-23:41: Other companies in the field 23:41-24:52: Working with Eli Lilly 24:52-27:15: A new frontier in medicine? 27:15-28:43: Cost effectiveness 28:43-30:07: Clinical trials 30:07-31:48: Applications to other diseases Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

1
Can Tumor Activated Therapy kill solid tumors? 31:22

منذ 5 weeks31:22

31:22

Solid tumors present a big challenge for current treatments. However, a new approach might provide the answers - Tumor Activated Therapy. By targeting specific proteins common in all solid tumor micro-environments, Seekyo scientists think this can induce self-destruction of the tumor itself. Seekyo’s lead therapy, SKY01, can only be activated within the tumor, making it a highly-targeted solution. This differentiated approach overcomes the limits of existing treatments, such as small molecule or antibody-drug conjugates. It could also be more cost effective than many advanced, far cell and gene therapy alternatives. Seekyo is looking for clinical entry to target four of the more challenging solid cancers - pancreas, TNBC, colorectal and lung, in an umbrella PhI/IIa. This will demonstrate safety and initial efficacy readings whilst at the same time defining the lead indication to progress to later-stage development. This week, our guest is Seekyo Therapeutics’ CEO, Oury Chetboun. 00:38-01:57: About Seekyo Therapeutics 01:57-03:17: The challenges of treating solid tumors 03:17-06:08: What is Tumor Activated Therapy? 06:08-07:46: What is SKY01? 07:46-08:10: What happens to the cancer cells? 08:10-09:52: Does the tumor vanish? 09:52-10:16: How is it delivered? 10:16-11:30: Are other companies working on tumor-activated therapies? 11:30-13:09: What treatment options are being worked on for solid tumors? 13:09-13:47: Long-lasting treatment 13:47-15:33: Clinical trials 15:33-16:22: Timelines 16:22-18:08: Does the treatment have other potential applications? 18:08-19:59: Cost effectiveness 19:59-21:59: Is the goal to cure people? 21:59-22:46: Treatment frequency 22:46-24:00: The impact of tumor size 24:00-25:23: Seekyo Therapeutics’ pipeline 25:23-27:27: Fund-raising 27:27-30:33: Reaction to the therapy Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

1
J.P. Morgan Annual Healthcare Conference 2025: trends and highlights you may have missed 19:57

منذ 6 weeks19:57

19:57

This week, we take a look at some of the highlights from the 43rd Annual J.P. Morgan Healthcare Conference, which took place in San Francisco recently. While there weren’t necessarily many financial blockbusters, there were plenty of announcements and discussions on everything from artificial intelligence to the rising influence of Chinese companies and research, to the potential ramifications of the incoming Trump administration in the U.S. To help us navigate some of the highlights of the event, we spoke with Orca Bio’s co-founder and CEO, Ivan Dimov, and also Parabilis Medicines’ chief business officer, Greg Miller. 02:01-03:53: About Orca Bio 03:53-05:43: JPM highlights 05:43-07:26: Stand-out deals and announcements 07:26-09:01: Were any sectors more prominent than others? 09:01-12:38: About Parabilis Medicines 12:38-13:58: JPM highlights 13:58-16:33: Stand-out deals and announcements 16:33-17:53: Were any sectors more prominent than others? 17:53-19:17: Was there an optimistic mood? Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

1
Venture capital co-creation: The next big thing in biotech investment? 37:22

منذ 7 weeks37:22

37:22

Jessica Owens and Iana Dimkova are co-founders of Initiate Ventures—a female-led venture capital firm and studio that launched recently with a $45 million debut fund. Initiate Ventures is shaking up the traditional venture capital model by blending investments in healthcare, life sciences, and technology with a company creation platform. The company is tackling some of the most pressing challenges in healthcare, and their innovative approach offers fresh insights into what it takes to scale transformative startups. Owens was the co-founder of GRAIL (acquired by Illumina for $8bn) and was a partner at Kleiner Perkins, where she helped shape some of the most successful health tech startups. Dimkova is a former healthcare technology investor at GE Ventures, who also scaled a company that raised more than $700m and built one of the largest radiation therapy networks in the US. Their approach is reflected in their dual model: funding existing companies while also co-creating ventures alongside founders in their startup studio. They helped launch groundbreaking companies like Macro Trials, a precision clinical research platform, and Persana, a leader in oncology diagnostics. This week on the podcast, we have a conversation with one of the co-founders of the company, Jessica Owens. 00:40-05:19: About Initiate Ventures 05:19-08:33: What sets Initiate Ventures apart from other venture funds? 08:33-10:59: Revitalizing healthcare 10:59-13:46: Determining realistic company visions 13:46-15:15: Initiate Ventures and Initiate Studios 15:15-19:50: Working with companies 19:50-21:36: Working with new companies 21:36-23:00: Evaluating potential success 23:00-24:40: How hands on is Initiate Ventures? 24:40-28:24: Is there a change in what attracts capital? 28:24-30:02: Infectious disease – a neglected area 30:02-33:08: How important are ESG considerations? 33:08-35:42: Trends for 2025 35:42-36:42: Goals for 2025 Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

1
Developing non-opioid pain drugs 33:01

منذ 8 weeks33:01

33:01

Brixton Biosciences, a clinical-stage life sciences company spun out from Massachusetts General Brigham, has been awarded $2m from the NIH HEAL Initiative to support the development of non-opioid, injectable pain relief solutions. As part of the NIH's efforts to tackle the U.S. opioid crisis, the funding will advance research into safer, drug-free alternatives to opioid pain management. Brixton’s Neural Ice is an injectable, drug-free pain management technology designed to provide long-lasting relief from chronic and post-operative pain. On the podcast this week, we have a conversation with Sameer Sabir, CEO and co-founder of Brixton Biosciences, to dive deeper into pain treatment, the opioid crisis, and Brixton’s mission. 01:05-02:47: About Brixton Biosciences 02:47-03:39: Brixton’s pipeline 03:39-07:46: The opioid crisis 07:46-08:41: The extent of the crisis 08:41-12:00: Current alternatives to opioids 12:00-12:40: Managing pain 12:40-17:19: How was Neural ice developed? 17:19-18:33: Duration of treatment 18:33-21:01: Suitability for different levels of pain 21:01-21:31: Speed of effect 21:31-22:37: Side effects 22:37-24:18: Opioids vs. non-opioids 24:18-25:33: Are there different responses to Neural Ice? 25:33-26:29: Standardized doses 26:29-27:42: Pricing 27:42-28:49: Other work on alternatives to opioids 28:49-30:45: Challenges to developing new pain treatments 30:45-31:57: Other priorities at Brixton 31:57-32:16: Timeline for Neural Ice Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

1
[Rebroadcast] The power of natural killer cells 28:59

منذ 10 weeks28:59

28:59

While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on January 3rd, 2025! Have an awesome holiday season! On this podcast , we speak to Artiva Biotherapeutics’ CEO, Fred Aslan, M.D. The company has demonstrated the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials. In August 2023, the company announced FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell therapy in autoimmune disease. AlloNK (also known as AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers in the out-patient setting. Artiva is investigating AlloNK in a phase 1/2 multicenter clinical trial to assess the safety and clinical activity of AlloNK alone and in combination with the anti-CD20 monoclonal antibody, rituximab, in patients with relapsed or refractory B-cell-non-Hodgkin lymphoma (B-NHL). Artiva is also investigating the safety and clinical activity of AlloNK in combination with rituximab in patients with lupus nephritis. In addition, Artiva is collaborating with Affimed in a phase 2, open-label, multi-center, multi-cohort study, testing a combination therapy, comprised of AlloNK and the innate cell engager AFM13, for the treatment of patients with relapsed/refractory CD30-positive lymphomas. Artiva selects cord blood units with the high affinity variant of the CD16 receptor and a KIR-B haplotype for enhanced product activity. Using the company’s cell therapy manufacturing platform, Artiva can generate thousands of doses of pure, cryopreserved, infusion-ready NK cells from a single umbilical cord blood unit while retaining the high and consistent expression of CD16 and other activating NK receptors, without the need for engineering. AlloNK is being administered in the outpatient setting over multiple doses and multiple cycles. Artiva’s pipeline also includes AB-201, an anti-HER2 CAR-NK cell therapy candidate for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers, and for which an IND has been allowed by FDA, and a pipeline of CAR-NK candidates targeting both solid and hematopoietic cancers. Artiva has also entered into therapeutic NK cell collaborations with Merck Sharp & Dohme. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

1
Looking at 2025 biotech trends with SoftBank Vision Fund 39:04

منذ 11 weeks39:04

39:04

Our guest on the podcast this week is John Cassidy, director of life sciences and healthtech investments at SoftBank Vision Fund. Softbank Vision Fund is the world’s largest technology-focused investment fund, with $166bn assets under management, and a portfolio of more than 250 companies. In the discussion, we cover investment trends within life sciences, the European health and biotech scene, as well as the precise applications of new and emerging AI technologies. We also look ahead to what the biotech and life sciences fields may hold in 2025. 00:55-02:03: About the SoftBank Vision Fund 02:03-02:47: Developing timelines 02:47-04:27: Managing a large portfolio 04:27-11:18: Portfolio company profiles 11:18-13:36: Investment criteria 13:36-17:06: Trends in funding 17:06-19:09: Effects of the US election 19:09-21:45: How can companies reduce risk and raise funds? 21:45-25:25: What sectors are attracting interest currently? 25:25-27:49: Focusing on patients not profits 27:49-29:53: The impact of AI 29:53-31:45: Focus on applications 31:45-35:24: Trends in European biotech funding 35:24-38:19: Trends for 2025 Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

1
Finding new treatments for peanut allergy 31:06

منذ 12 weeks31:06

31:06

There is a constant risk of severe, potentially life-threatening allergic reactions for individuals with peanut allergies, which leads to significant physical, social, and emotional burdens. IgGenix, a clinical-stage immunology biotechnology company, recently announced the first patient dosed in its phase 1 trial evaluating IGNX001, a novel monoclonal antibody-based therapeutic, for peanut allergy. Designed to neutralize the most clinically important peanut allergens and epitopes, IGNX001 combats peanut allergies by blocking the allergic cascade and reducing risk of anaphylaxis. Should IGNX001 prove successful, it will provide a promising solution for peanut allergies and pave the way for IgGenix's technology to be applied to other types of food allergies and allergic diseases. Our guest on the podcast this week is Jessica Grossman, chief executive officer of IgGenix. 01:14-02:51: About IgGenix 02:51-06:30: About peanut allergy 06:30-07:31: Are allergies on the rise? 07:31-08:46: Are allergy responses similar? 08:46-10:13: The problems with treating allergies 10:13-13:53: Current treatments for peanut allergy 13:53-15:45: The challenges of developing drugs to treat allergies 15:45-16:54: Overcoming the placebo effect 16:54-18:18: Are other companies working on allergy treatments? 18:18-21:32: IgGenix’s SEQ SIFTER platform 21:32-24:20: About IgGenix’s IGNX001 24:20-24:42: Repeat doses 24:42-26:19: Could peanut allergy sufferers eat peanuts? 26:19-27:46: Can the technology be adapted to treat other allergies? 27:46-28:56: Are there variations in the treatment of different allergies? 28:56-29:35: Treatments for other diseases 29:35-30:23: The future for people with allergies Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

1
Cracking the code of biotech valuations 37:43

منذ 13 weeks37:43

37:43

ambiom is a life science commercial-advisory business development company based in the Slovakian capital of Bratislava. The company helps its corporate clients with their product strategy, in- and out-licensing efforts, including asset valuation (NPV, rNPV), M&A scouting, complex due diligence and dealmaking. ambiom also provides input on regulatory matters, support in pricing and reimbursement decisions and communication with decision-making authorities. The company guides products from the beginning - the basic science - all the way to commercialization or spin-offs. Our guest on the podcast this week is the founder and CEO of ambiom, Adam Marťák. We discuss the biotech scene in eastern Europe, the company, and look at some of the challenges facing biotech companies as they navigate the financial pathway alongside drug discovery, regulations, and commercialization. 00:45-02:33: About ambiom 02:33-03:11: ambiom clients 03:11-04:21: Biotech in eastern Europe 04:21-11:35: Focusing on a niche 11:35-13:13: What do startups need? 13:13-15:19: How do you help startups? 15:19-16:52: Tech transfer 16:52-18:35: Early-stage and late-stage biotech valuations 18:35-21:48: Different valuation methods 21:48-22:53: Why do early-stage biotech valuations offer higher upside potential for investors? 22:53-23:42: How do you measure the value of pipeline potential? 23:42-24:35: Does a bigger pipeline guarantee more success? 24:35-27:08: Can companies look more attractive to investors? 27:08-28:41: Does pipeline speed affect investment? 28:41-30:27: Which valuation method is better for biotech companies? 30:27-31:46: Are some areas of biotech better for valuations? 31:46-33:18: What affects valuation? 33:18-35:13: The difference between financing of expensive and cheaper drugs 35:13-36:57 : Is funding more difficult now, and is it changing? Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

1
Can biotech beat mosquito-borne diseases? 35:59

منذ 14 weeks35:59

35:59

Biological control company Oxitec recently launched Sparks, a new platform designed to rapidly scale Wolbachia replacement technology to take on dengue fever. Backed by a multi-million-dollar investment from the Gates Foundation, Sparks adds to Oxitec’s Aedes aegypti technology, called Friendly, which is taking on dengue fever in Brazil. With mosquito-borne diseases on the rise, Oxitec’s Friendly mosquitoes are designed to suppress populations of disease-spreading mosquitoes and, in turn, reduce biting and the threat of disease transmission. Wolbachia-carrying mosquitoes are designed to spread Wolbachia bacteria into the local mosquito population to limit the ability of the remaining infected mosquito population to transmit dengue. The platforms are designed for specific settings and intervention types, and provide options for governments and communities seeking suppression, replacement or hybrid approaches using both. Our guest on the podcast this week is the CEO of Oxitec, Grey Frandsen. 00:56-02:12: About Oxitec 02:12-05:54: The state of mosquito-borne diseases 05:54-07:09: The effect of climate change 07:09-08:29: Moving into more developed countries 08:29-10:27: Wolbachia replacement technology 10:27-12:53: The Sparks program 12:53-13:46: Other companies’ approaches 13:46-15:00: World Mosquito Program 15:00-15:30: Establishing timelines 15:30-17:20: The effect on the environment 17:20-18:54: Could adaptation render the technology useless? 18:54-20:52: Are the Sparks and Friendly programs being used together? 20:52-21:57: Do the technologies work differently on different species? 21:57-26:28: How to determine rollout conditions 26:28-27:19: Are repeat interventions needed? 27:19-30:32: Are there limitations based on cost or politics? 30:32-33:11: Are the technologies applicable to other problems? 33:11-35:08: Is there anything else in Oxitec’s pipeline? Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

1
Could antigen modulation address autoimmune diseases? 24:04

منذ 15 weeks24:04

24:04

Immunology is a key area in biotech and biopharma, both in terms of R&D and sales. However, according to UK-headquartered Greywolf Therapeutics, the industry has only focused on two-thirds of the puzzle. To have an immunological effect, you must activate the body’s T cells, which cells requires a chain of three key signals. The first is antigen recognition, i.e. the initial detection of a cell by a T-cell. The second is the co-stimulation of non-antigen presenting molecules, which enhances the immune response. The final step is cytokine-mediated differentiation and expansion, which guides how T-cells target threats. Companies have focused on the second two signals, with signal 2 most commonly seen in therapies such as checkpoint inhibitors and monoclonal antibodies. Signal 3, on the other hand, can be primarily seen in therapies for autoimmune disorders, such as anti-TNF and JAK inhibitors. Greywolf Therapeutics is the first company to explore changing signal 1. The company says focusing on signal 1 applies in three key therapeutic areas: oncology, autoimmunity and virology. Greywolf’s first candidate has delivered strong results during its ongoing phase I/II trial in oncology, therefore demonstrating proof-of-mechanism and target engagement, with its next candidate well-progressed in preclinical development in autoimmunity. To tell us more about the company and its work is Pete Joyce, CEO and co-founder of Greywolf Therapeutics. 01:19-04:12: About Greywolf Therapeutics 04:12-04:51: The origins of the name 04:51-06:52: The three ‘signals’ of the mechanics of immunological responses 06:52-08:31: Treatments associated with each signal 08:31-10:09: Why is step 1 important, and why has it not been investigated for treatments? 10:09-11:28: What areas of disease is this applicable to? 11:28-12:19: How do you inhibit ERAP? 12:19-14:01: Greywolf Therapeutics’ candidates 14:01-15:11: How is this an advance on current treatments? 15:11-16:05: What is success for patients? 16:05-17:20: How does the stage of disease affect treatment? 17:20-18:09: Are other companies looking into antigen modulation? 18:09-19:47: Has this led to investment opportunities? 19:47-21:15: Next steps 21:15-21:55: Do you anticipate more interest in this space? 21:55-23:21: Attending events Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

1
Beyond profits: The Bill & Melinda Gates MRI's mission to combat neglected diseases 38:10

منذ 16 weeks38:10

38:10

The Bill & Melinda Gates Medical Research Institute (Gates MRI) is a non-profit medical research organization dedicated to the development and effective use of products like drugs, vaccines and monoclonal antibodies to address substantial global health concerns, for which investment incentives are limited, including malaria, tuberculosis, diarrheal diseases, and diseases that impact maternal, newborn, and child health. This week, our guest is Dr Claire Wagner, head of corporate strategy and market access at Gates MRI. Wagner has dedicated her life to global health. Her early years working in West Africa and East Africa – including five years working with the Rwanda Ministry of Health – were formative experiences for her. She helped document health sector outcomes in Rwanda and had a front row seat to the progress the country was making at the time, which led to her pursuing and obtaining an MD and MBA from Harvard. Her experiences led to her becoming one of the early employees of the Gates MRI, where she is on the executive leadership team and leads the institute's global access strategy as well as related engagement with commercial partners, financial institutions and multilaterals. She tackles the challenge of paving the way for the drugs, biologics and vaccines that the Gates MRI is developing – if they are successful in clinical trials – to be affordable and accessible to the people in low- and middle-income countries who would benefit most. In March 2024 the Gates MRI launched a phase 3 clinical trial for a tuberculosis vaccine candidate, and market access for this candidate is a top priority for Wagner. 01:51-04:47: Background on Dr Claire Wagner 04:47-06:24: Work in Rwanda 06:24-08:40: Gates MRI 08:40-12:50: Progress at Gates MRI 12:50-14:06: Gates MRI R&D priorities 14:06-16:26: The differences between Gates MRI and traditional biotechs 16:26-18:40: Gates MRI partnerships 18:40-22:52: The inequality of developing drug treatments 22:52-25:45: Return on investment 25:45-27:01: Did COVID increase global awareness? 27:01-27:44: Other companies working on treatments 27:44-31:48: Gates MRI pipeline and clinical trials 31:48-34:51: Working on tuberculosis 34:51-36:00: Treatment mode of action 36:00-37:25: Future work at Gates MRI Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
How to succeed as a woman in biotech 34:12

منذ 17 weeks34:12

34:12

This week, we are taking a look at an important subject, and that is women working as CEOs, or other senior roles, in the biotech space. Kate Yen is the CEO of oncology biotech Auron Therapeutics, and she has spent her entire career in science. Auron is working on the next generation of targeted cancer therapies by identifying and inhibiting the oncogenic cell states of cancer. Auron’s AURIGIN platform uses AI and machine learning to compare normal cell states with cancerous cell states to identify novel cancer targets, optimal development models, and biomarkers to guide patient selection. Auron is building a pipeline of small molecule targeted therapies, led by AUTX-703, which is being developed for the treatment of solid tumors and hematologic malignancies, including acute myeloid leukemia. 02:16-07:44: About Kate Yen and Auron Therapeutics 07:44-09:09: The challenges of setting up a company 09:09-11:56: Auron Therapeutics’ lead candidate 11:56-12:52: The rest of the pipeline 12:52-13:29: Auron timeline 13:29-15:01: Are there specific challenges being a female biotech CEO? 15:01-15:49: Is there support for women in biotech beyond the CEO level? 15:49-16:51: Helping others 16:51-17:41: Challenges in the boardroom 17:41-18:40: Diversity in biotech 19:40-21:03: Changing mindsets 22:05-22:59: Being a role model 22:59-24:43: Attracting women from outside hubs 25:42-27:28: Diversity and education 27:28-31:31: The importance of AI 31:31-32:34: The evolution of Auron Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter This week’s podcast is sponsored by Cryoport Systems, the global leader in comprehensive temperature-controlled supply chain solutions, is proud to introduce IntegriCell™ to preserve the future of medicine. IntegriCell™ cryopreservation services provide an integrated, end-to-end solution to ensure the highest quality, consistency, and viability of manufacture-ready, cryopreserved leukopaks for cell therapies. IntegriCell™ enables seamless, efficient, and reliable cryopreservation services combined with end-to-end supply chain solutions to support the treatment of patients worldwide. For more information, visit Cryoport.com .…

Beyond Biotech - the podcast from Labiotech

1
The immunometabolism landscape 30:13

منذ 18 weeks30:13

30:13

Sitryx Therapeutics is a private UK biopharma company founded in 2018. It is a leader in the field of immunometabolism, an area of immunology that looks to rebalance the immune system to achieve sustained disease remission in autoimmune and inflammatory diseases. Sitryx already has big pharma validation following a deal with Eli Lilly in 2020 worth in excess of $1 billion and is focused on advancing its pipeline of potentially first- and best-in-class therapies, which could address a wide range of chronic conditions, including SYX-5219 for atopic dermatitis. The company has a broad pipeline of small molecules against novel targets in major autoimmune indications with high unmet need. To talk about immunometabolism, our guest on the podcast this week is CEO of Sitryx Therapeutics, Iain Kilty. 00:52-01:48: About Sitryx 01:48-02:32: What is immunometabolism? 02:32-05:01: Approaches to address autoimmune and inflammatory diseases 05:01-06:46: Drug development 06:46-08:29: What is Sitryx’s approach? 08:29-11:02: Finding diseases to treat 11:02-13:09: About SYX-5219 13:09-16:08: Inflammatory response 16:08-18:40: About SYX-1042 and Eli Lilly 18:40-19:54: Mode of delivery 19:54-20:49: The Sitryx pipeline 20:49-22:08: Research on immune cell function and other companies’ work 22:08-23:53: Increased interest in the field 23:53-25:06: More investment and deals 25:06-26:30: Future treatments of autoimmune and inflammatory diseases 26:30-27:59: The future of immunometabolism 27:59-29:26: Sitryx’s goals Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
Biotech beyond earth: The future of medicine in space 39:01

منذ 19 weeks39:01

39:01

LinkGevity, founded by two sisters, is developing anti-necrotic technologies, especially for application in kidney disease. Carina Kern is the CEO of the company, while Serena Kern-Libera is the chief operating officer. After reading an article about how space-travel is especially damaging to the kidneys, they applied for a place on the inaugural NASA Space-H Accelerator program, and how medicine can support human deep-space missions. LinkGevity was selected for the program, which is in its inaugural year. LinkGevity was selected as its research has uncovered technology with significant potential to minimize the health and performance risks in human spaceflight. LinkGevity’s anti-necrotics applications cover four major areas: organoid preservation and growth; cryopreservation; organ growth and preservation; and kidney protection. LinkGevity’s novel proprietary Blueprint Theory of Aging, developed by Kern, offers a multi-disciplinary framework for understanding the development of age-related diseases and deterioration. The theory enables the company’s AI to accurately identify and target key biological pathways involved in aging and deterioration, with necrosis being one of the most critical processes addressed. To talk about the company’s technology, and its application to space, we had a conversation with Carina Kern and Serena Kern-Libera. 01:48-05:45: About LinkGevity 05:45-06:39: What is the goal for LinkGevity? 06:39-09:07: Is early intervention important? 09:07-11:10: What is the Blueprint Theory of Aging, and how do you identify and target key biological pathways involved in aging and deterioration? 11:10-13:51: Applying the theory 13:51-15:03: Necrosis and LinkGevity’s Anti-Necrotic technology 15:03-18:37: Blocking necrosis and treating disease 18:37-19:06: Drug delivery 19:06-20:54: The importance of AI 20:54-24:43: Connecting LinkGevity’s work with space 24:43-26:24: The SPACE-H program 27:18-28:13: Other biotech involvement in the program 28:13-30:13: LinkGevity’s presentation at Space-Comm 30:13-31:00: Keeping space medicine simple 31:00-32:18: The future for LinkGevity 32:18-33:14: LinkGevity’s timescale 33:14-33:47: Clinical trials 33:47-34:53: LinkGevity’s future space work 34:53-35:30: Different space opportunities 35:30-38:12: LinkGevity funding Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
The future of gene therapy 33:25

منذ 20 weeks33:25

33:25

Today, gene therapy is at an exciting inflection point as the industry moves beyond the first generation of these therapies. However, challenges and barriers remain in bringing gene therapies to market, particularly as they expand into more prevalent diseases . Spur Therapeutics is a clinical-stage biotech company dedicated to developing next generation gene therapies for people living with chronic, debilitating diseases. Its lead candidate, FLT201, is an AAV gene therapy for Gaucher disease that is poised to enter phase 3 development in 2025. This week, we have a conversation with Michael Parini, CEO of Spur Therapeutics, about the future of gene therapy. 01:56-04:01: About Spur Therapeutics 04:01-06:49: Where is the gene therapy field at currently? 06:49-10:44: The biggest challenges for gene therapies, and potential solutions 10:44-13:21: What is the next generation of gene therapy? 13:21-18:08: How can gene therapy be used to take on more diseases? How can it be cheaper? 18:08-19:14: Are other companies working on next-generation gene therapies? 19:14-21:07: What is Gaucher disease? 21:07-22:32: How are you tackling Gaucher disease? 22:32-26:07: What is the measure of success? 26:07-28:18: About adrenomyeloneuropathy 28:18-29:32: Upcoming approvals in gene therapy 29:32-31:40: How quickly is gene therapy evolving? This podcast is sponsored by Vetter, a globally leading CDMO, with over 70 years of experience as a responsible, independent family business. Driven by more than 6,600 employees worldwide, Vetter provides life-saving injectable drug products to the patients that rely on them most. Vetter partners with its customers throughout the entire product lifecycle, starting in the early phase of drug development with comprehensive expertise and support in clinical manufacturing for in-human trial material. For more information, visit vetter-pharma.com Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
Bispecific ADCs: the next generation of cancer treatments 29:45

منذ 21 weeks29:45

29:45

Antibody-drug conjugates have been an area of great interest in the oncology space in recent years, with a record rate of FDA approvals and dealmaking activity. However balancing efficacy and off-site toxicity has remained a challenge. Some biopharma companies are investing in what they hope will be the next-generation approach to ADCs – bispecific ADCs. More than a dozen early-stage clinical trials are evaluating whether adding a second targeting functionality can improve the preciseness of ADCs’ tumor-targeting, as well as potentially overcome the challenge of heterogeneity in solid tumor target expression. Bispecific ADCs have been a hot area for dealmaking over the past year, including BMS’ $8.4 billion purchase of a bispecific ADC candidate in December, a $690 million deal between Biotheus and Hansoh this spring, and the recently announced $325 million deal between Prague-based SOTIO Biotech and Biocytogen. SOTIO’s most advanced ADC, SOT102, is now in a phase 1/2 clinical study in the U.S. and Europe. To talk about biotechs in Czechia, and bispecific ADCs, our conversation this week is with Radek Špíšek, CEO of SOTIO. 01:22-03:17: About SOTIO 03:17-06:12: Are there many biotech or biopharma companies in Prague? 06:12-08:16: Are there any challenges or opportunities being in Prague? 08:16-13:21: What are bispecific ADCs and how do they differ from regular ADCs? 13:21-15:37: Are there any challenges using bispecific ADCs? 15:37-17:07: What are the benefits of bispecific ADCs? 17:07-18:40: Do bispecific ADCs address the challenge of balancing efficacy and off-site toxicity? 18:40-19:42: Why are bispecific ADCs such a hot topic? 19:42-21:35: Deals involving bispecific ADCs, and SOTIO’s partnership with Biocytogen 21:35-24:15: What is SOT102? 24:15-26:41: What else is in SOTIO’s pipeline? 26:41-27:47: What is the future for bispecific ADCs? 27:47-29:01: What does this mean for patients? Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated of the latest biotech news by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
Targeting telomerase to disrupt cancer 26:30

منذ 22 weeks26:30

26:30

Telomeres are structures made from DNA sequences and proteins, and they are found at the ends of chromosomes. In effect, they cap and protect the end of a chromosome. Telomerase is an enzyme that adds DNA to the ends of chromosomes, and it is reactivated in most cancers. Most human tumors not only express telomerase but also have very short telomeres. This makes telomerase a prime target for cancer therapies. MAIA Biotechnology is focused on the pioneering approach of telomere targeting through its lead therapeutic strategy, THIO. Currently, MAIA is making strides with THIO in a phase 2 clinical trial aimed at combating high-risk non-small cell lung cancer (NSCLC). THIO targets telomerase, thus disrupting cancer cells’ vital structures, leading to their rapid demise. To tell us about MAIA’s groundbreaking work, and the relationships between telomeres, telomerase and cancer, is the CEO and chairman of the company, Vlad Vitoc. 01:16-02:13: About MAIA Biotechnology 02:13-06:24: What is the role of telomerase in cancer? 06:24-07:02: Do other factors affect telomeres? 07:02-08:42: How does your therapy, THIO, work? 08:42-09:08: Safety of THIO 09:08-10:54: How is it administered? 10:54-11:04: Are there other companies working on this? 11:04-12;14: What else is in the MAIA pipeline? 12:14-17:18: MAIA clinical trials 17:18-18:19: Could THIO be a preventative treatment? 18:19-19:46: Is there a lot of research on telomeres and telomerase? 19:46-21:06: Are there cancers that are not telomerase positive? 21:06-21:41: What is the future for telomere-targeting therapies? 21:41-23:14: Are there any challenges? 23:14-25:40: Is word spreading about your treatments? Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
Harnessing the body’s natural targeted protein degradation system to treat diseases 34:04

منذ 23 weeks34:04

34:04

C4 Therapeutics (C4T) is a leader in the targeted protein degradation (TPD) field, with two oncology drug candidates currently in clinical trials and collaborations with pharma companies like Merck, Biogen and Roche. The clinical-stage biopharmaceutical company is dedicated to creating a new generation of medicines using its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. TORPEDO can design molecular glues and heterobifunctional degraders, giving C4T the capability of targeting almost any disease-causing protein. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. C4T is led by CEO and president Andrew Hirsch, who is this week’s guest on the podcast. 01:17-03:01: About C4 Therapeutics 03:01-05:07: What is targeted protein degradation? 05:07-06:21: What kind of diseases can TPD be used to address? 06:21-10:53: What are the different TPD strategies: PROTAC, molecular glue, lysosome-targeting chimaera (LYTAC), and antibody-based PROTAC? 10:53-12:43: How are those strategies applied? 12:43-13:59: How is TPD improving on current treatments? 15:39-18:24: What is your discovery program, TORPEDO, and how does it work? 18:24-25:19: About C4T clinical trials 25:19-26:13: Reaction to the ESMO presentation 26:13-28:50: Partnerships with pharma companies 28:50-31:26: Are there any hurdles or challenges in using TPD? 31:26-33:23: The future of TPD Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
Estonia's biobank: Is this the first large-scale personalized medicine initiative? 32:15

منذ 24 weeks32:15

32:15

Estonia is working on becoming the first country to implement personalized health at scale through the Estonian National Biobank. The biobank uses genetic data to create a picture of the Estonian population, leading to the potential adaptation of public health systems. The Estonian Biobank has samples from 20% of the adult population; in comparison, UK biobanks only represent 0.7% of the population. With so much data, Estonia can determine risk factors for cancer, cardiovascular disease, mental and reproductive health, informing health investments to improves patient outcomes. The project seeks to predict patients’ responses to certain medications based on their genetic makeup. As well as better patient outcomes, this approach could save health systems millions on ineffective prescriptions in the long run. It could also be a blueprint for other national health systems, including the NHS, to personalize healthcare at scale. Earlier this year, the Estonian Biobank announced the next phase of its European Commission funded project in collaboration with sequencing firm PacBio. On the podcast this week, we have Professor Lili Milani, head of the Estonian National Biobank, and Neil Ward, VP of EMEA at PacBio. 01:27-04:06: What is the Estonian National Biobank? 04:06-05:15: Background on PacBio 05:15-06:43: What are the benefits of using genetic data to create a picture of the Estonian population? 06:43-08:24: What data is collected, and how is it used? 08:24-09:54: Protecting individual privacy 09:54-11:24: Is the databank used regularly by Estonian citizens? 11:24-12:35: Can the biobank help address disease earlier? 12:35-16:30: Are there economic savings? 16:30-17:16: How to expand the biobank program 17:16-19:44: How does the biobank help personalize medicine? 19:44-20:26: Are there regional differences? 20:26-21:57: How can Estonia’s system be applied to other countries? 21:57-22:57: Has there been international interest in the biobank? 22:27-22:52: Are pharma companies interested in the biobank? 22:52-24:05: The partnership with PacBio 24:05-26:15: Is AI being used in conjunction with the biobank? 26:15-27:26: Is the biobank project similar to other PacBio work? 27:26-29:00: What is the future for the biobank relationship with PacBio? 29:00-31:30: What is the future for the biobank? Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
Targeting inflammation: A revolution in disease treatment 43:10

منذ 25 weeks43:10

43:10

Inflammation appears to affect almost every part of the human body as we age, including cancer, type-2 diabetes, obesity, and neurodegenerative disorders. NLRP3 inflammasome-induced inflammation is at the root of nearly all disease pathologies including fibrotic, dermatological, rheumatological diseases as well as neurological disorders such as Alzheimer’s disease. Halia Therapeutics is a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation. Halia Therapeutics’ candidates are the first drugs to target the protein NEK7 to inhibit NLRP3 inflammasome activity to resolve chronic inflammation in multiple diseases. Its lead candidate, HT-6184 is currently being evaluated in two phase II studies – for the treatment of post-procedure inflammatory pain response and cancer (lower-risk myelodysplastic syndromes (LR-MDS). The company also recently announced a new collaboration to leverage AI in the clinical development of its new Alzheimer's disease drug, HT-4253, targeting a mediator of neuroinflammation called leucine-rich repeat kinase 2 (LRRK2). This week, or guest is Dave Bearss, CEO of Halia Therapeutics. 01:09-05:49: About Halia Therapeutics 05:49-08:59: What is the difference between acute inflammation and chronic inflammation? 08:59-12:02: What is NLRP3 inflammasome-induced inflammation? 12:02-15:37: What is NEK7 and how does targeting it help inhibit NLRP3 inflammasome activity? 15:37-18:51: What diseases are related to NLRP3 inflammasome activity? 18:51-22:11: What does reducing NLRP3 activity address in these conditions? 22:11-26:46: With Alzheimer’s and Parkinson’s is inflammation reduction being investigated by other companies? 26:46-24:14: What is Halia’s lead candidate, HT-6184? 34:14-37:03: What is the balance between normal inflammation and reducing chronic inflammation? 37:03-38:34: Is early intervention the key? 38:34-42:18: Would your treatment be good as a preventative measure? Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
The power of tumor infiltrating lymphocytes to fight melanoma 38:03

منذ 26 weeks38:03

38:03

Tumor infiltrating lymphocyte (TIL) therapy uses a person’s own immune cells to fight advanced melanoma, offering new hope for patients who have limited treatment options. This week, we have a conversation with Brian Gastman, EVP of medical affairs at Iovance Biotherapeutics, about TILs and the company’s pipeline. Iovance recently submitted a marketing authorization application to the European Medicines Agency for lifileucel, a TIL cell therapy, for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. If approved, lifileucel will be the first and only approved therapy in this treatment setting in all European Union member states. The submission is supported by positive clinical data from the C-144-01 clinical trial in patients with advanced post-anti-PD1 melanoma. Iovance’s Amtagvi is the first FDA-approved T cell therapy for a solid tumor indication. 00:47-04:44: About Iovance Biotherapeutics 04:44-07:57: What is polyclonal tumor infiltrating lymphocyte treatment? 07:57-14:55: What is the production process for TILs? 14:55-18:32: Are there any limiting factors for TIL treatment? 18:32-20:59: Is early intervention important? 20:59-21:22: Does better psychology help? 21:22-22:06: Are other companies working on TILs? 22:06-27:25: Clinical trials 27:25-29:25: How do you address cost? 29:25-34:21: Iovance’s pipeline 34:21-35:30: Can TILs be improved? 35:30-37:21: Where does the TIL space go from here? Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
The future of combination vaccines 24:44

منذ 27 weeks24:44

24:44

The development of combination vaccines could represent a significant advancement in the fight against infectious diseases. With the potential to streamline the vaccination process and provide broader protection, these vaccines could greatly improve public health preparedness. Moderna is harnessing the power of its mRNA platform to develop vaccines that target multiple respiratory viruses at once, including COVID-19, RSV, and influenza. The breakthrough technology enables the immune system to combat multiple pathogens simultaneously, revolutionizing immunization efforts and enhancing public health preparedness. To look at combination vaccines, their usefulness and potential for the future, we had an in-depth conversation with Cesar Sanz Rodriguez, vice president, Europe & Switzerland, medical affairs, at Moderna. 00:45-02:53: What is combination vaccine technology? 02:53-05:33: What are the advantages of targeting multiple respiratory diseases simultaneously? 05:33-06:02: Making vaccinations more friendly 06:02-07:57: How does the immune system handle tackling many pathogens at the same time? 07:57-10:23: Is there an effect of efficacy with combination vaccines? 10:23-12:50: How do you manage different times between boosters? 12:50-13:57: Are many companies working on combination vaccines? 13:57-17:45: How easy is it to add vaccines, for example to tackle avian flu, into combination vaccines? 17:45-19:06: Is there a limit to the number of vaccines in a combination vaccine? 19:06-20:46: How easily can vaccines be updated to address variants? 20:46-22:30: What is the future of combination vaccines? 22:30-23:56: What is in Moderna’s pipeline related to vaccines? Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
New German biotech spins out to develop radiotherapeutics 18:35

منذ 28 weeks18:35

18:35

Pentixapharm is a clinical-stage radiopharmaceutical development company targeting a range of diseases. While it is currently owned by the Eckert & Ziegler Group, it will soon be spun off as a separate company. Pentixapharm’s clinical pipeline includes PENTIXATHER, am Yttrium-90 based therapeutic against CNS lymphoma, and PENTIXAFOR, a Gallium-68 based companion diagnostic. Additionally, PENTIXAFOR is being developed as a diagnostic tool for primary aldosteronism (PA), a significant cause of hypertension. Recently, the company announced the acquisition of the target discovery business of Glycotope. The deal includes a portfolio of preclinical antibodies against multiple oncology targets that can be developed into radiopharmaceuticals. It also includes Glycotope’s laboratories, cell banks, tumor target data base, and the equipment needed to exploit the discovery platform, along with a range of patents, licenses, and other tangible assets. This week, we had a conversation with Andreas Eckert, founder and chairman of the supervisory board at Pentixapharm. 00:57-03:07: About the Pentixapharm spinout 03:07-05:19: What is Pentixapharm’s pipeline? 05:19-06:01: What is the CXCR4 ligand approach? 06:01-08:51: What are the development plans for tackling primary aldosteronism? 08:51-10:28: Is the process fast, and what about cost? 10:28-11:47: The bigger economic picture 11:47-14:12: About Glycotope 14:12-14:44: How synergistic are Pentixapharm and Glycotope? 14:44-15:32: Is the entire company being acquired? 15:32-16:27: Will outsourcing still be important to the company? 16:27-17:55: What does the future hold for Pentixapharm? Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
Challenging the European biotech funding status quo 36:36

منذ 29 weeks36:36

36:36

There are many questions when it comes to setting up a biotech company, and raising funds. Currently, many companies are concerned about fundraising, but there are things that can be done to maximize efforts. Does a company’s location affect fundraising? What is the best approach to successfully raise funds? What are the current trends in biotech funding? To look at questions surrounding the state of European biotech funding, and how it compares with the global scene, intellectual property, and how to challenge the status quo, we have a conversation with Dima Kuzmin, managing partner at 4BIO Capital. 4BIO is an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other emerging technologies. 00:45-02:36: About 4BIO 02:36-07:39: What are the trends in biotech investments currently? 07:39-09:30: Is being in a well-known biotech hub necessary to raise funds? 09:30-14:14: Is relocation necessary for companies starting up if they aren’t near a biotech hub? 14:14-17:57: What differences are there in investment patterns between Europe, the US and Asia? 17:57-21:35: How can funding match the research strength there is in Europe? 21:35-25:07: Are there any emerging hubs in Europe, or opportunities to create new hubs? 25:07-26:36: Are Spain and Italy good locations for biotech? 26:36-28:32: What are the best ways for European companies to attract US and Asian capital? 28:32-35:47: How do you see the European biotech space evolving? Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
[Rebroadcast] Epigenetic editing – the power of CRISPR without cutting DNA 32:57

منذ 30 weeks32:57

32:57

While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on August 16, 2024! Have an awesome summer! Epic Bio is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector. This week, we discuss epigenetic editing, why it’s reversible, and how it can treat FSHD and other conditions, with Epic Bio’s founder, Dr Stanley Qi, one of the original inventors of CRISPR. 01:15-02:51: Dr Xi’s background 02:51-05:11: The beginning of Epic Bio 05:12-09:23: What is epigenetic editing? 09:23-10:47: What is the Gene Expression Modulation System? 10:47-12:47: How is the editing reversible? 12:47-18:01: How will epigenetic editing advance treatments? 18:01-21:24: Tackling multiple conditions 21:24-22:46: How will your platform tackle FSHD? 22:46-24:18: FSHD clinical trial 24:18-25:51: How will you address costs? 25:51-27:18: Are other companies working on epigenetics? 27:18-29:27: What else is in the pipeline? 29:27-31:58: What are the next steps? Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

Beyond Biotech - the podcast from Labiotech

1
[Rebroadcast] How does AI assist drug discovery? 38:40

منذ 31 weeks38:40

38:40

While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on August 16, 2024! Have an awesome summer! Artificial intelligence (AI) is certainly in the news constantly; however, it’s been used in drug discovery for some time. A new collaboration between artificial intelligence drug discovery company Insilico Medicine and University of Toronto biochemist and molecular geneticist Igor Stagljar will test AI-designed molecules against "undruggable" cancer targets. The research will test 15 to 20 undruggable targets - but are they undruggable? And how does AI work in the drug discovery process? This week, we have a conversation with Kyle Tretina, Alliance Manager of AI Platforms at Insilico Medicine, on a wide range of subjects including drug discovery, undruggable targets, the collaboration with the University of Toronto, and more. 00:58-05:11: About Insilico Medicine 05:11-06:09: Why is AI in the news? 06:09-07:39: Helping people through AI 07:39-09:10: What is Insilico Medicine doing with AI? 09:10-10:15: Does Insilico Medicine take drugs from idea to trials? 10:15-11:32: How do your partnerships come about? 11:32-19:34: How does drug development start with AI? 19:34-24:43: Can AI address undruggable targets? 24:43-25:05: What do you need to do after finding a potential drug? 25:05-27:57: Can quantum computing aid drug development? 27:57-30:13: How can AI help reduce costs and save time? 30:13-32:56: What is your partnership with the University of Toronto? 32:56-36:24: What is the timescale for introducing drugs from AI? 36:24-37:29: What conditions are you working on? Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter…

مرحبًا بك في مشغل أف ام!

يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.